Why the study?
There is currently no established screening tool for cardiac amyloidosis, leading to delayed diagnosis in most patients.
Does an AI algorithm based on three-dimensional ECGs reliably screen for cardiac amyloidosis in patients with cardiovascular diseases?
Does an AI algorithm based on three-dimensional ECGs reliably screen for cardiac amyloidosis in patients with cardiovascular diseases?
A novel AI algorithm using three-dimensional ECGs provides reliable non-invasive screening for cardiac amyloidosis with a high negative predictive value.
Answers are grounded in this paper and cite their sources.
Supports noninvasive amyloid screening in CV disease; leaves open prospective outcome trials before clinical adoption.
AIMS: Currently, there is no established screening tool for cardiac amyloidosis, leading to a delay in diagnosis in the majority of patients. We aimed to develop and validate a non-invasive and easy to use tool that allows for screening of cardiac amyloidosis based on structured evaluation of three-dimensional electrocardiograms (ECGs). METHODS AND RESULTS: We included patients with confirmed cardiac AL or ATTR amyloidosis and controls of patients with other cardiovascular diseases but without amyloidosis into two independent cohorts: a derivation and validation cohort. All patients received three-dimensional ECGs and vector loops were categorized based on predefined patterns by two independent cardiologists. Consecutively, an AI algorithm was trained in the derivation cohort (n = 66 amyloidosis cases, n = 89 controls). This algorithm was then applied to the validation cohort (n = 33 amyloidosis cases, n = 67 controls). Overall, 99 patients with amyloidosis and 156 controls were included (mean age: 69 ± 15 years, 79% male). In the derivation cohort, the AI algorithm reached a sensitivity of 85%, a specificity of 89%, a positive predictive value of 91%, and a negative predictive value of 87%. Applying the algorithm on the independent validation cohort, a sensitivity of 79%, specificity of 82%, a positive predictive value of 61%, and a negative predictive value of 92% was reached. CONCLUSIONS: We here describe a novel screening tool, which allows for reliable detection of cardiac amyloidosis.
No takes yet. Share an insight, caveat, or question.
Mahabadi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: